Ensign Peak Advisors’s Adaptive Biotechnologies ADPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.7M Buy
127,989
+7,219
+6% +$177K 0.01% 640
2026
Q2
$2.59M Sell
120,770
-70
-0.1% -$1.07K ﹤0.01% 686
2026
Q1
$1.68M Sell
120,840
-19,327
-14% -$308K ﹤0.01% 742
2025
Q4
$2.28M Sell
140,167
-9,810
-7% -$160K ﹤0.01% 680
2025
Q3
$2.24M Buy
+149,977
New +$1.83M ﹤0.01% 775
2022
Q4
– Sell
-14,700
Closed -$105K – 1791
2022
Q3
$105K Hold
14,700
– – ﹤0.01% 2081
2022
Q2
$119K Sell
14,700
-14,562
-50% -$128K ﹤0.01% 1928
2022
Q1
$406K Sell
29,262
-43,832
-60% -$689K ﹤0.01% 1640
2021
Q4
$2.05M Sell
73,094
-9,970
-12% -$306K ﹤0.01% 942
2021
Q3
$2.82M Buy
83,064
+6,032
+8% +$218K 0.01% 917
2021
Q2
$3.15M Sell
77,032
-5,711
-7% -$222K 0.01% 858
2021
Q1
$3.33M Sell
82,743
-12,385
-13% -$670K 0.01% 814
2020
Q4
$5.62M Sell
95,128
-18,303
-16% -$944K 0.01% 570
2020
Q3
$5.52M Buy
113,431
+52,549
+86% +$2.21M 0.01% 599
2020
Q2
$2.94M Sell
60,882
-7,599
-11% -$277K 0.01% 781
2020
Q1
$1.9M Buy
68,481
+60,033
+711% +$1.67M 0.01% 855
2019
Q4
$252K Buy
+8,448
New +$243K ﹤0.01% 1609

Other funds holding ADPT

Ensign Peak Advisors's ADPT Position: Q3 2026 in Review

Ensign Peak Advisors increased its Adaptive Biotechnologies (ADPT) stake by 6% in Q3 2026, buying an estimated $177K and bringing the position to 127,989 shares worth $3.7M. The position accounts for 0.01% of the portfolio, ranked #640.

Ensign Peak Advisors first reported a position in ADPT in Q4 2019 and has held it in 17 quarters since. The position peaked at $5.62M in Q4 2020. 334 funds tracked by Wall St. Rank hold ADPT as of Q3 2026.

  • Ensign Peak Advisors held 127,989 shares of Adaptive Biotechnologies worth $3.7M as of Q3 2026.
  • Ensign Peak Advisors bought 7,219 Adaptive Biotechnologies shares in Q3 2026, an estimated $177K.
  • Adaptive Biotechnologies made up 0.01% of Ensign Peak Advisors's portfolio in Q3 2026, its #640 holding.
  • Ensign Peak Advisors first reported a position in Adaptive Biotechnologies in Q4 2019 and has held it in 17 quarters since.
  • Ensign Peak Advisors's Adaptive Biotechnologies position peaked at $5.62M in Q4 2020.
  • 334 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2026.

Based on Ensign Peak Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.